Research Paper Volume 13, Issue 15 pp 19750—19759

Dual inhibition of FGFR4 and BCL-xL inhibits multi-resistant ovarian cancer with BCL2L1 gain

BCL2L1 is frequently gained in OvCa. Reproduced from TCGA OvCa dataset, shown were (A) copy number alteration of Cytoband 20q11.21 that encompassed BCL2L1; (B) frequency of gain (pink) and amplification (red) of BCL2L1 across all cancers in TCGA dataset; (C) differential expression of BCL2L1 across TCGA cancers; (D) Reproduced from CPTAC dataset, shown were protein level of BCL2L1 in different clinicopathological parameters; (E) representative IHC images of BCL2L1 in normal ovary tissue and ovarian cancer tissue; (F) overall and progression-free survival of OvCa cases with or without BCL2L1 gain/amplification in TCGA cohort; (G) overall survival of OvCa cases with top 30% or bottom 30% of BCL2L1 expression in TCGA cohort (*P

Figure 1. BCL2L1 is frequently gained in OvCa. Reproduced from TCGA OvCa dataset, shown were (A) copy number alteration of Cytoband 20q11.21 that encompassed BCL2L1; (B) frequency of gain (pink) and amplification (red) of BCL2L1 across all cancers in TCGA dataset; (C) differential expression of BCL2L1 across TCGA cancers; (D) Reproduced from CPTAC dataset, shown were protein level of BCL2L1 in different clinicopathological parameters; (E) representative IHC images of BCL2L1 in normal ovary tissue and ovarian cancer tissue; (F) overall and progression-free survival of OvCa cases with or without BCL2L1 gain/amplification in TCGA cohort; (G) overall survival of OvCa cases with top 30% or bottom 30% of BCL2L1 expression in TCGA cohort (*P < .05; **P < .01; ***P < .001; ****P < .0001).